GlassScriptPhysician profile
Mark D Gulinson
NPI 1881698264
$11,149.50
in general payments reported to CMS, 2019-2025
36 companies · $2,882 in 2025
The $2,882 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $691 · 2021: $1,338 · 2022: $1,251 · 2023: $1,720 · 2024: $2,102 · 2025: $2,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,638 · Education: $67.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,637.66 |
| Education | $67.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,756.93 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,271.35 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $1,208.40 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $852.82 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $820.68 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $601.42 | 2022-2025 | |
| Pfizer INC. | $512.87 | 2019-2025 | |
| Madrigal Pharmaceuticals | $406.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $343.74 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $259.13 | 2019-2023 | Dificid |
| Phathom Pharmaceuticals, INC. | $229.58 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $212.97 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $211.70 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $180.93 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $171.22 | 2019-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $166.20 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Ipsen Biopharmaceuticals, INC | $158.50 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $136.80 | 2021-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $101.02 | 2022-2023 | Cimzia, Rebyota |
| Ardelyx, INC. | $93.38 | 2022 | |
| Ucb, INC. | $86.04 | 2019 | |
| Alfasigma USA, INC. | $42.98 | 2020 | |
| Aimmune Therapeutics, INC. | $38.45 | 2024-2025 | Zenpep |
| Evoke Pharma, INC. | $38.19 | 2024 | |
| Shionogi INC | $38.00 | 2019 | |
| Daiichi Sankyo INC. | $28.92 | 2019 | |
| Abbott Laboratories | $27.07 | 2024 | Proclaim |
| Mallinckrodt Hospital Products INC. | $25.36 | 2024 | Terlivaz |
| Exact Sciences Corporation | $23.13 | 2025 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $19.55 | 2024 | Oxlumo |
| Alexion Pharmaceuticals, INC. | $18.58 | 2019 | |
| Shield Therapeutics INC | $18.36 | 2024 | |
| Capsovision, INC. | $17.13 | 2023 | Capsocam Plus |
| Braintree Laboratories, INC. | $16.17 | 2023 | Sutab |
| Teva Pharmaceuticals USA, INC. | $15.39 | 2025 | Simlandi |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$52,173.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gulinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.